Top
Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
DOI: 10.5009/gnl19433, Volume: 15, Issue: 2, Pages: 232-242
Article Type: research-article,
Article History
received:
rev-recd:
accepted:
published:
-
-
-
- Altmetric
https://www.researchpad.co/tools/openurl?pubtype=&doi=10.5009/gnl19433&title=Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis&author=&keyword=[{keywordId=6074, uniqueName=infliximab, name=Infliximab, contentId=55356}, {keywordId=27640, uniqueName=colitis-ulcerative, name=Colitis, ulcerative, contentId=55356}, {keywordId=27641, uniqueName=adalimumab, name=Adalimumab, contentId=55356}, {keywordId=27642, uniqueName=tumor-necrosis-factor-alpha, name=Tumor necrosis factor-alpha, contentId=55356}, {keywordId=57111, uniqueName=comparative-study, last=true, name=Comparative Study, contentId=55356}],[{keywordId=6074, uniqueName=infliximab, name=Infliximab, contentId=55356}, {keywordId=27640, uniqueName=colitis-ulcerative, name=Colitis, ulcerative, contentId=55356}, {keywordId=27641, uniqueName=adalimumab, name=Adalimumab, contentId=55356}, {keywordId=27642, uniqueName=tumor-necrosis-factor-alpha, name=Tumor necrosis factor-alpha, contentId=55356}, {keywordId=57111, uniqueName=comparative-study, last=true, name=Comparative Study, contentId=55356}],[{keywordId=6074, uniqueName=infliximab, name=Infliximab, contentId=55356}, {keywordId=27640, uniqueName=colitis-ulcerative, name=Colitis, ulcerative, contentId=55356}, {keywordId=27641, uniqueName=adalimumab, name=Adalimumab, contentId=55356}, {keywordId=27642, uniqueName=tumor-necrosis-factor-alpha, name=Tumor necrosis factor-alpha, contentId=55356}, {keywordId=57111, uniqueName=comparative-study, last=true, name=Comparative Study, contentId=55356}],[{keywordId=6074, uniqueName=infliximab, name=Infliximab, contentId=55356}, {keywordId=27640, uniqueName=colitis-ulcerative, name=Colitis, ulcerative, contentId=55356}, {keywordId=27641, uniqueName=adalimumab, name=Adalimumab, contentId=55356}, {keywordId=27642, uniqueName=tumor-necrosis-factor-alpha, name=Tumor necrosis factor-alpha, contentId=55356}, {keywordId=57111, uniqueName=comparative-study, last=true, name=Comparative Study, contentId=55356}],[{keywordId=6074, uniqueName=infliximab, name=Infliximab, contentId=55356}, {keywordId=27640, uniqueName=colitis-ulcerative, name=Colitis, ulcerative, contentId=55356}, {keywordId=27641, uniqueName=adalimumab, name=Adalimumab, contentId=55356}, {keywordId=27642, uniqueName=tumor-necrosis-factor-alpha, name=Tumor necrosis factor-alpha, contentId=55356}, {keywordId=57111, uniqueName=comparative-study, last=true, name=Comparative Study, contentId=55356}],&subject=
© 2024 Newgen KnowledgeWorks |
Privacy & Cookie Policy | Powered by: Nova